Pfizer: Prevnar 13 Effective in Young Adults

The 13-valent pneumococcal polysaccharide conjugate vaccine (Prevnar 13) elicits as strong an immune response in adults 18 to 49 as it does in those ages 60 to 64, according to Phase III results reported by Pfizer, the vaccine’s maker.
MedPage Today